IL17A and breast cancer: Extending studies beyond classic Th1 and Th2 lymphocyte polarization, additional studies have implicated IL-17 in canine MGT malignancy, progression, and metastases (158); findings that are comparable to human breast cancer studies showing IL-17 to be a negative biomarker for prognosis and shorter disease-free intervals (164).